Skip to main content
. 2018 Apr 12;13(4):e0195909. doi: 10.1371/journal.pone.0195909

Fig 3. Elimination of TMDD and enhanced FcRn recycling are additive.

Fig 3

(A) PK of surrogate anti-mouse C5 mAbs BHL011 (✖), BHL006 (■) and BHL009 (▲) after a single 100 μg IV dose in hFcRn transgenic mice (n = 5 per group). (B) Corresponding ex vivo complement classical pathway hemolytic activities.